Litigation

Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc.

affirmed

2020-2106

Terminated
2022-02-10

Patents at issue (1)

Summary

Federal Circuit appeal from the D.N.J. invalidity judgment. On February 10, 2022, the court affirmed, finding no error in the obviousness conclusion as to the asserted claims including U.S. 9,629,965 claims 21, 24, and 25; Newman, J., dissented.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).